Metrics as of 10/17/2026, 08:49 AM (Berlin time), refresh in progress.
Oncolytics Biotech Stock
Oncolytics Biotech Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jared Kelly
- Employees
- 29
- Market cap
- $50 M
- IPO
- 05/10/2001
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor…
Oncolytics Biotech stock: price history
1D
-9.0%
1W
-10.6%
1M
-35.2%
6M
-55.5%
YTD
-43.0%
1Y
-57.4%
2Y
-60.2%
5Y
-77.6%
10Y
-77.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~1% stronger price swings than usual
Ask the agents about Oncolytics Biotech
Analyst assessment of Oncolytics Biotech
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 19/08/2026
Oncolytics Biotech stock metrics
P/E
-2.05
P/B
-13.68
EV/EBITDA
-1.77
RETURN ON EQUITY
153.1%
NET MARGIN
0.0%
DEBT/EQUITY
-0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
116.5%
FLOAT SHARES
116,895,373
AVG. DAILY VOLUME (30D)
1,395,259
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Oncolytics Biotech stock
What does Oncolytics Biotech do?
Oncolytics Biotech Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jared Kelly, the company employs around 29 people.
The IPO was on 05/10/2001; the stock trades on NASDAQ under the ticker ONCY.
What do analysts say about Oncolytics Biotech stock?
10 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Oncolytics Biotech report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Oncolytics Biotech pay a dividend?
No, Oncolytics Biotech currently does not pay a dividend.
Which stocks are comparable to Oncolytics Biotech?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Oncolytics Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oncolytics Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.